Triple-negative breast cancers (TNBCs), which lack expression of the estrogen receptor alpha (ERα), progesterone receptor, and human epidermal growth factor receptor 2 (HER2), are particularly aggressive and clinically challenging to manage due to the absence of these common therapeutic targets [1]. Here, ESR1 is linked to triple-negative breast carcinoma.